Association Between Coagulation Fibrinolysis Markers and Severity in Patients with COVID-19
Clinical and Applied Thrombosis/Hemostasis · 2024
DOI: 10.1177/10760296241298233 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2024. Verfasst von Takuya Iwamoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Laboratory Medicine, Tottori University Hospital, Yonago, Tottori, Japan. Hauptthemen laut MEDLINE: COVID-19, Fibrinolysis, Biomarkers, Severity of Illness Index. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Thrombosis is a major complication of COVID-19. D-dimer (DD) is an important coagulation fibrinolysis marker in COVID-19 and has been extensively studied. However, very little is known about the role of other fibrinolysis markers, plasmin-plasmin inhibitor complex (PIC), and fibrin monomer complex (FMC) in COVID-19. This study investigated and compared the associations of DD, PIC, and FMC with COVID-19 severity.
Methods
Archived plasma samples from patients with COVID-19 (n = 50) were assessed for DD, FMC, and PIC levels. We compared the levels between patients with mild (n = 36) and moderate (n = 14) COVID-19 and evaluated their correlation with other COVID-19 severity markers, including lactate dehydrogenase (LD), serum albumin (Alb), C-reactive protein (CRP), and neutrophil-lymphocyte ratio (NLR).
Results
Patients with moderate COVID-19 had significantly higher DD and PIC levels than those with mild disease, while FMC levels were comparable. DD and PIC levels significantly correlated with LD, Alb, and NLR. Additionally, PIC levels significantly correlated with CRP levels. However, FMC levels correlated only with Alb but not with LD, NLR, or CRP.
Conclusions
COVID-19 severity was significantly associated with PIC and DD levels but not with FMC levels. PIC was the variable with the most clearly significant difference between patients with moderate disease and those with mild disease, highlighting its potential as an indicator of coagulation and fibrinolysis imbalance in patients with COVID-19. Further studies with larger sample sizes and more diverse severity groups are required to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Laboratory Medicine, Tottori University Hospital, Yonago, Tottori, Japan.
- Department of Multidisciplinary Internal Medicine, School of Medicine, Tottori University Faculty of Medicine, Yonago, Tottori, Japan.
- Department of Hematology, Tottori University Hospital, Yonago, Tottori, Japan.
ORCID-Profile: Takuya Iwamoto, Yuki Hatayama
Zitieren
APA
Iwamoto, T., Hatayama, Y., Yamashita, N., Ichikawa, H., & Kawamura, K. (2024). Association Between Coagulation Fibrinolysis Markers and Severity in Patients with COVID-19. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296241298233
Vancouver
Iwamoto T, Hatayama Y, Yamashita N, Ichikawa H, Kawamura K. Association Between Coagulation Fibrinolysis Markers and Severity in Patients with COVID-19. Clinical and Applied Thrombosis/Hemostasis. 2024. doi:10.1177/10760296241298233
BibTeX
@article{Iwamoto2024,
author = {Iwamoto, Takuya and Hatayama, Yuki and Yamashita, Noriko and Ichikawa, Hitomi and Kawamura, Koji},
title = {Association Between Coagulation Fibrinolysis Markers and Severity in Patients with COVID-19},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2024},
doi = {10.1177/10760296241298233}
}
EUVIMED